601607 上海医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入139,413,1465.14%260,295,089231,981,300215,824,259191,909,156
减:营业总成本134,890,1695.21%253,008,864224,907,251209,641,475185,559,849
    其中:营业成本123,245,1616.67%228,966,947201,494,923187,281,149165,180,104
               财务费用705,939-8.70%1,485,7581,313,1921,245,3691,239,584
               资产减值损失(36,526)-155.26%(561,277)(331,471)(140,441)(898,616)
公允价值变动收益114,289-41.94%404,731218,738(206,004)116,798
投资收益246,363-223.81%(68,123)533,1171,811,394976,195
    其中:对联营企业和合营企业的投资收益365,613-658.88%129,329526,743789,5961,009,547
营业利润4,830,8975.99%7,667,2359,014,6508,205,4867,184,388
利润总额4,822,0216.36%7,054,2978,808,3538,143,8157,175,483
减:所得税费用1,224,6589.66%1,887,7261,816,3391,869,2451,570,219
净利润3,597,3635.28%5,166,5706,992,0156,274,5695,605,264
减:非控股权益655,452-18.80%1,398,5711,374,8631,181,1021,109,047
股东净利润2,941,91112.72%3,768,0005,617,1525,093,4674,496,217

市场价值指针
每股收益 (元) *0.79011.27%1.0201.6101.7901.580
每股派息 (元) *0.080--0.4100.6100.4200.480
每股净资产 (元) *18.8983.90%18.50018.13717.36715.958
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容